A total of 588 blood specimens collected in an emergency unit were screened for benzodiazepines (BZDs) using enzyme-multiplied immunoassay and gas chromatography. Two-hundred eighty-five samples were positive for BZDs, and 303 samples that were negative by EMIT | included 20 samples with BZDs detectable by gas-liquid chromatography. A total of 15 BZDs were identified, and the most frequently occurring were nordiazepam, bromazepam, diazepam, and alprazolam. Individual BZDs were found in 74% of cases, but some samples contained two, three, or even four BZDs. There is a risk of missing intoxication by BZDs with low therapeutic range and/or low cross-reactivity (alprazolam, bromazepam, flunitrazepam). There is a risk of misinterpreting a positive result for some BZDs with high therapeutic range and/or high cross-reactivity (nordiazepam), which may reflect a pharmacologically ineffective concentration. A semiquantitative analysis is inappropriate even when the identity of BZD is known. Immunoassays are the only methods presently available for use in emergencies, but physicians must be clearly informed of their limitations and interpret results with caution.
Introduction
Benzodiazepines (BZDs) are widely prescribed as anxiolytic, sedative, hypnotic, and muscle-relaxant drugs (1, 2) and are among the most common agents implicated in deliberate and accidental overdosages. BZDs are generally thought to be safe in overdose (3) , but fatal poisonings have been attributed to BZDs, with or without alcohol (4) . The most reliable methods used in forensic laboratories to identity and quantitate BZDs include gas chromatography (GC) coupled to an electron-capture detector (5, 6) or a mass spectrometer (MS) (7, 8) and highpressure liquid chromatography (9) (10) (11) . However, immuno-* Author to whom correspondence should be addressed.
assay screening (12) (13) (14) is the most common and rapid method for checking for BZD abuse and assisting the physician involved in the care and management of the intoxicated patient. The concentrations of BZD compounds that produce a result equivalent to that of the cutoff calibrator in fluorescence polarization immunoassays (FPIA) and enzyme immunoassays (EIA) vary markedly between BZDs because of differences in cross-reactivity. The therapeutic ranges of BZDs are also very different from one to another. However, immunoassay results indicate the presence of BZD and may be interpreted as an indication of intoxication by physician. However, a positive result may also indicate normal therapeutic concentrations of some BZDs. This work was carried out to define the percentage of real BZD overdoses identified by enzyme-multiplied immunoassay (EMIT) and how they are influenced by the chemical nature of the BZD.
Methods

Samples
A total of 588 blood specimens collected during four periods over 1 year from patients admitted to the emergency unit of a Regional University Hospital Center (2200 beds) were sent to the toxicology laboratory for routine drug screening. This was done using enzyme-multiplied immunoassay (EMIT-d.a.u) (15) . Serum samples were then frozen at -20~ until GC analysis, screening, BZD identification, and a second quantitation.
Chemicals and reagents
Standards of alprazolam (APZ) and triazolam (TRZ) were obtained from Upjohn (Puurs, Belgium); bromazepam (BMZ), clonazepam (CNZ), diazepam (DZP), flunitrazepam (FNZ), and nitrazepam (NTZ) were obtained from Produits Roche (Basel, Switzerland); clobazam (CBZ) and desmethylclobazam (DMC) were obtained from Diamant (Paris-La Defense, France); lorazepam (LRZ), oxazepam (OXZ), and temazepam (TMZ) were obtained from Wyeth (Paris-La Defense, France); nordiazepam (NDZ) was obtained from Bouchara (Paris, France); prazepam (PZP) was obtained from Parke-Davis (Morris Plains, N J); and tetrazepam (TTZ) was obtained from Sanofi Winthrop (Gentilly, France). The pure products were dissolved in methanol (Protabo, Paris, France). Chloroform, sodium hydroxide, and Titrisol | buffer (boric acid/potassium chloride/sodium hydroxide) were obtained from Merck (Darmstadt, Germany). Double-distilled and pyrogen-free water (Biosedra | was purchased from Fresenius France (Louviers, France).
EMIT test
The autocarousel, spectrophotometer and clinical processor Cobas Mira Plus and EMIT-d.a.u reagent kits were supplied by Syva-Behring (Rueil-Malmaison, France). The absorbance was set at 340 nm, and the absorbance change (AA) was recorded. Assays were performed according to the manufacturer's instructions. The calibrator containing 200 ng/mL oxazepam was used as cutoff, and the response of this calibrator was arbitrarily set to 1000 (hA). The calibrator level 0 (AA = 874 + 18; n = 12) and the calibrator containing 2000 ng/mL diazepam (hA = 2119 + 40; n = 12) were used as controls: The concentrations of BZDs that produced assay results approximately equivalent to calibrator oxazepam level 200 ng/mL were collected in Table  I . When the assay is used as a qualitative assay, a positive result indicates that samples contain benzodiazepine or benzodiazepine metabolites. When semiquantitative determinations are desired, a standard curve should be prepared by plotting the A values of the different available calibrators. Some compounds, including amphetamine, benzoylecgonine, chlorpromazine, dextromethorphan, fenoprofen, ibuprofen, methadone, methaqualone, morphine, naproxen, phencyclidine, propoxyphene, and secobarbital, produced a negative response.
Gas-liquid chromatography (GLC) screening
Extraction. Methylclonazepam (internal standard, 10 ng), 200 tJL water, and 100 IJL 1N NaOH were added to 200 IJL serum and extracted with 500 IJL chloroform in glass test tubes (polytef-lined screw cap) that had been rinsed with chloroform.
The samples were shaken for 6 rain and centrifuged for 10 rain at 3500 rpm. The upper aqueous phase was discarded, and an aliquot (1 IJL) of the lower organic phase was injected directly into the chromatograph. 
GC-MS identification
Extraction. IN NaOH (200 laL) was added to 1 mL serum and extracted with 3 mL chloroform. The samples were shaken for 6 min and centrifuged for 10 min at 3500 rpm. The upper phase was discarded, the lower organic phase was evaporated to dryness, and the residue was dissolved in 20 laL CH3OI-I.
Chromatography. The GC-MS was an ion-trap Varian Saturn series II (Varian Chromatography Systems). A 50% methylphenyl silicone (15 m x 0.32 ram, 0.25-lam film thickness) capillary column (Hewlett Packard, Les Ulis, France) was used with a deactivated retention gap connected to a programmable temperature injector heated from 60~ to 280~ at 180~ and held for 5 rain. The oven was initially held at 65~ for 1 min, ramped to 250~ at 15~ then held for 6.67 min. The pressure applied to the helium carrier gas was 0.6 bar. The MS was run in electron-impact ionization mode.
Peak identification. 
GLC quantitation
Extraction. Calibration curves for BZDs identified by GC-MS were prepared by spiking 100 IaL human serum (13iotrol 00A, Biotrol, Paris, France) with four concentrations of BZDs (Table  II) . When the sample concentrations covered both therapeutic and toxic ranges, two calibrations, low (l) and high (h), were done. Samples with very high concentrations were diluted 1:5, 1:10, 1:50, and 1:100, and the appropriate dilution within the calibration range was retained. Methylclonazepam was added as internal standard in suitable amounts. Depending on the amount of internal standard, Titrisot buffer (pH 11,500 IJL) and CHC13 were then added to each sample.
Chromatography. The GC system was the same as that used for GLC screening. The operating conditions used provided optimal resolution with minimal run time for each BZD. The chromatographic conditions were as follows: solid injector and detector temperature, 280~ column temperature, isothermal at 240~ (CBZ, DMC, DZP, NDZ, TTZ), 250~ (APZ), 260~ (BMZ), or temperature programmed from 210~ (1.25 min) to 260~ (1.75 rain) at 12.5~ (FNZ, LRZ, PZP). The pressure applied to the helium carrier gas was 0.3 bar (BMZ), 0.4 bar (CBZ, DMC, DZD, LRZ, NDZ, TTZ), or 0.8 bar (FNZ, PZP, APZ).
Chromatographic runs took 6.5-8 rain. The mean extraction recovery was 95 • 2%. The mean within duplicate precision was 6.6 • 1.1%, and the mean between-control variation was 8.2 + 1.5%. The minimum detectable concentrations were 4 ng/mL (FNZ), 10 ng/mL (APZ), 20 ng/mL (BMZ, LRZ), 50 ng/mL (CBZ), 100 ng/mL (DZP, NDZ, PZP), and 200 ng/mL (DMC, TTZ).
Results
A total of 588 serum samples were analyzed using the immunoenzymatic assay. Two-hundred eighty-five samples were positive, and 303 samples had undetectable BZDs. All 285 positive samples were confirmed by GLC to contain BZDs. Quantitation showed 246 samples contained toxic concentrations and 39 samples contained therapeutic concentrations. The 303 undetectable samples (by EMIT) included 20 samples with BZDs detectable by GLC: 15 samples contained toxic concentrations, and 5 contained therapeutic concentrations.
Analysis of the 305 (285 + 20) samples that were positive by GLC identified 388 BZDs (parent drug or metabolite), because some samples contained two, three, or even four BZDs. A total of 15 BZDs were identified (Figure 1) The BZDs concentrations were classified as below, within, or above the therapeutic range (15) of the parent BZD. The number of samples, the mean plus or minus standard deviation (SD), and the range for each group are shown in Table III . The concentration of the dealkylated metabolite is also reported when it was measured. The distributions of the concentrations of the most common BZDs (alprazolam, bromazepam, and nordiazepam) in relation to therapeutic range is shown in Figure  2 . Associations of two BZDs were detected in 46 cases and the mean (2 SD) concentrations are given in Table IV (245 ng/mL), nordiazepam (260 ng/mL), and oxazepam (455 ng/mL), and the other case had flunitrazepam (35 ng/mL), prazepam (230 ng/mL), its dealkylated metabolite nordiazepam (325 ng/mL), and oxazepam (4065 ng/mL).
Each group of BZDs found alone was analyzed to determine the correlation between the change in absorbance (AA) when analyzed by EMIT and the concentration (C) determined by GLC (Figure 3) . The best correlations were obtained using logarithmic functions. The correlation coefficients varied widely from 0.418 (bromazepam; n = 82; p < 0.01) to 0.680 (alprazolam; n = 24; p < 0.01) to 0.834 (nordazepam; n = 99; p < 0.01). There was no significant correlation for flunitrazepam (0.609; n = 7) or tetrazepam (0.519; n = 8). The slopes of the regression lines of ~A plotted against Log C and the intercepts also differed greatly (Figure 3) . 
Discussion
The EMIT immunoassay is intented for the qualitative and semiquantitative analysis of BZDs in human urine and serum. The assay is based on competition between the BZD in the sample and BZD labeled with the enzyme glucose-6-phosphate dehydrogenase for antibody-binding sites. The BZD concentration is measured as enzyme activity converting nicotinamide adenine dinucleotide (NAD) to NADH, which gives change in absorbance that is measured spectrophotometrically. Comparison of the AA obtained with an unknown to that for a calibrator containing oxazepam (200 ng/mL; automatically set to 1000) is used to determine the BZD in the sample. A standard curve was prepared by plotting the AA for three concentrations of calibrator for semiquantitation.
All 285 samples that were positive by EMIT were confirmed to contain BZDs, indicating that the binding sites are specific and that there is little or no interference from other drugs. Therapeutic doses of oxaprozin, a nonbenzodiazepine, may give positive results with this immunoenzymatic assay, but this is the only interference reported (16) . 
Sample number
The 20 samples containing BZDs that gave a AA lower than the calibrator contained mainly three BZDs, alprazolam, bromazepam, and flunitrazepam. This poor response is linked to their low cross-reactivity and the low therapeutic range of some of these BZDs. The 24 samples containing alprazolam included six samples with toxic concentrations that were not detected by immunoassay. The 82 samples containing bromazepam included four samples containing therapeutic concentrations, but six samples containing toxic concentrations were undetectable by EMIT. The risk of failure in intoxication screening is thus not negligible, especially for these two BZDs.
Nordiazepam was the most frequently found BZD. This agrees with the fact that nordiazepam is given as a proprietary preparation, but it is also the most common metabolite of BZDs such as chlordiazepoxide, clorazepate, diazepam, and prazepam. Clorazepate is essentially a pro-drug for desmethyldiazepam and is rapidly decarboxylated in the acidic conditions of the stomach (17) . Prazepam is pharmacologically inactive, and there are only trace amounts of intact prazepam in the blood according to therapeutic monitoring (18 cases of nordazepam intoxication (n = 99) because it is rapidly glucuronoconjugated and eliminated in the urine (18) . The 10 samples in which large amounts of oxazepam were found with nordiazepam suggest that the parent NDZ and OXZ were ingested at the same time.
The data were classified into three groups according to the therapeutic range of each BZD in order to differentiate real intoxications from ! o o therapeutic concentrations in positive EMIT responses. This classification is influenced by the 9 C therapeutic range, which may vary from 1 to 15 ng/mL (flunitrazepam) to 200 to 800 ng/mL (nordiazepam), and the intensity of the cross-reaction in the immunoassay, which also varies nordiazepam concentration that is pharmacologically ineffective ( Figure 2 ). The assay literature states that a positive result indicates the presence of BZDs but does not indicate or measure intoxication. The present work assists physicians who need to know the nature and concentration of BZDs in a population of subjects suspected of being intoxicated. The patient and/or his/her family can be questioned, and knowledge of their disorder and its drug treatment may give valuable clues for interpreting analytical results. The association of parent BZD with dealkylated, hydroxylated or other metabolites, or other BZDs interferes with the immunochemical reaction, and makes interpretation more difficult. For example, some toxic concentrations of bromazepam were undetectable with EMIT test when therapeutic concentrations were detectable. The semiquantitative analysis of BZDs is very questionable (Figure 3) . Although there is a correlation when many samples are tested, the data scatter and the differences in slopes and intercepts precluded even rough quantitative results. The unknown relative ratios of parent BZD to several metabolites that cross-react differently in the immunoassay make semiquantitative estimation very uncertain even when the identity of the BZD is known.
This analysis of the distribution of BZDs in samples screened using an immunoassay has shown that BZDs are found alone in 74% of cases, associated with their dealkylated metabolite in 11% of cases, and associated with other BZDs in 15% of cases. Nordazepam and bromazepam were the most frequently identified BZDs. There is a risk of missing intoxication by BZDs with a low therapeutic range. A positive response for BZDs with a high therapeutic range may indicate a pharmacologically inactive concentration. Lastly, a semiquantitative analysis is inappropriate. Immunoassays are the only methods presently available for use in an emergency. They are generally fast, but physicians must be clearly informed of their limitations, interprete results with caution, and request identification of the BZD when the patient's clinical state is incompatible with the laboratory data.
